Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension

Journal of the American College of Cardiology

Volumn 60, Issue 14, 2012, Pages 1271-1277

  Geisler, Benjamin P ^a   Egan, Brent M ^b   Cohen, Joshua T ^c   Garner, Abigail M ^a   Akehurst, Ronald L ^d   Esler, Murray D ^e   Pietzsch, Jan B ^a  

^a Wing Tech Inc   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

autonomic denervation; cost benefit analysis; decision support techniques; hypertension; renal artery

Indexed keywords

ADULT; ARTICLE; CATHETERIZATION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; KIDNEY FAILURE; LIFESPAN; LONG TERM CARE; MALE; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESISTANT HYPERTENSION; RISK ASSESSMENT; STROKE; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT PLANNING;

AGED; CARDIOVASCULAR DISEASES; CATHETERIZATION; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; RISK; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84866736657     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.07.029     Document Type: Article

References (26)

1. C.D. Fryar, R. Hirsch, M.S. Eberhardt, S.S. Yoon, J.D. Wright Hypertension, High Serum Total Cholesterol, and Diabetes: Racial and Ethnic Prevalence Differences in U.S. Adults, 1999-2006 NCHS Data Brief 2010 National Center for Health Statistics Hyattsville, MD
2. World Health Organization Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks 2009 World Health Organization Geneva, Switzerland
3. S.D. Persell Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 2011 1076 1080
4. M.P. Schlaich, P.A. Sobotka, H. Krum, E. Lambert, M.D. Esler Renal sympathetic-nerve ablation for uncontrolled hypertension N Engl J Med 361 2009 932 934
5. H. Krum, M. Schlaich, R. Whitbourn Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 2009 1275 1281
6. Symplicity HTN-1 Investigators Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months Hypertension 57 2011 911 917
7. Symplicity HTN-2 Investigators M.D. Esler, H. Krum, P.A. Sobotka, M.P. Schlaich, R.E. Schmieder, M. Böhm Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet 376 2010 1903 1909
8. A. de la Sierra, J. Segura, J.R. Banegas Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring Hypertension 57 2011 898 902
9. P.W. Sullivan, V. Ghushchyan Preference-based EQ-5D index scores for chronic conditions in the United States Med Decision Making 26 2006 410 420 (Pubitemid 44050845)
10. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York, NY
11. Bureau of Labor Statistics Consumer Price Index, 2011 ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt Accessed August 2012
12. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2004 National Heart, Lung, and Blood Institute Bethesda, MD
13. K. Lovibond, S. Jowett, P. Barton Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study Lancet 378 2011 1219 1230
14. B.M. Egan, Y. Zhao, R.N. Axon, W.A. Brzezinski, K.C. Ferdinand Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008 Circulation 124 2011 1046 1058
15. P.J. Neumann, E.A. Sandberg, C.M. Bell, P.W. Stone, R.H. Chapman Are pharmaceuticals cost effective? A review of the evidence Health Affairs 19 2000 92 109
16. H. Krum, N. Barman, M. Schlaich, P. Sobotka, M. Esler, F. Mahfoud Long-term follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction (abstr) J Am Coll Cardiol 59 2012 E1704
17. M. Esler, H. Krum, M. Schlaich, R. Schmieder, M. Böhm, P. Sobotka Renal sympathetic denervation for treatment of resistant hypertension: one year result from the Symplicity HTN-2 randomized controlled trial (abstr) J Am Coll Cardiol 59 2012 E1705
18. G.F. DiBona, M. Esler Translational medicine: the antihypertensive effect of renal denervation Am J Physiol Regul Integr Compar Physiol 298 2010 R245 R253
19. F. Mahfoud, M. Schlaich, I. Kindermann Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study Circulation 123 2011 1940 1946
20. W.G. Walker, J.D. Neaton, J.A. Cutler, R. Neuwirth, J.D. Cohen Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial Racial and treatment effects. The MRFIT Research Group JAMA 268 1992 3085 3091
21. P.A. Sobotka, H. Krum, M. Böhm, D.P. Francis, M.P. Schlaich The role of renal denervation in the treatment of heart failure Curr Cardiol Reports 14 2012 285 292
22. A. Witkowski, A. Prejbisz, E. Florczak Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea Hypertension 58 2011 559 565
23. K.C. Young, J.C. Teeters, C.G. Benesch, J.D. Bisognano, K.A. Illig Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator J Clin Hypertens (Greenwich) 11 2009 555 563
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and, Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
25. B. Dahlof, P.S. Sever, N.R. Poulter Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 2005 895 906 (Pubitemid 41265663)
26. M.D. Wong, M.F. Shapiro, W.J. Boscardin, S.L. Ettner Contribution of major diseases to disparities in mortality N Engl J Med 347 2002 1585 1592 (Pubitemid 35315840)